Antimicrobial resistance in urinary isolates from inpatients and outpatients at a tertiary care hospital in South-Kivu Province (Democratic Republic of Congo) by Leonid M Irenge et al.
Irenge et al. BMC Research Notes 2014, 7:374
http://www.biomedcentral.com/1756-0500/7/374SHORT REPORT Open AccessAntimicrobial resistance in urinary isolates from
inpatients and outpatients at a tertiary care
hospital in South-Kivu Province (Democratic
Republic of Congo)
Leonid M Irenge1,2,3*, Landry Kabego1, Olivier Vandenberg4, Raphael B Chirimwami1 and Jean-Luc Gala2,3Abstract
Background: The rate of antimicrobial resistant isolates among pathogens causing urinary tract infections (UTIs) in
Democratic Republic of Congo (DRC) is not known. The aim of the current study was to determine this rate at the
Bukavu Provincial General Hospital (province of South-Kivu, DRC).
Findings: A total of 643 isolates (both from inpatients and outpatients) collected from September 2012 to August
2013 were identified using biochemical methods, and tested for antimicrobial susceptibility. The isolates were
further screened for Extended-Spectrum Beta-Lactamases (ESBL) production. Beta-lactamase AmpC phenotype was
investigated in 20 antibiotic-resistant isolates.
Escherichia coli (58.5%), Klebsiella spp. (21.9%) and Enterobacter spp. (16.2%) were the most frequent uropathogens
encountered. Rare uropathogens included Citrobacter spp., Proteus spp., and Acinetobacter spp. Resistance was
significantly more present in inpatients isolates (22.1% of isolates) when compared to outpatients isolates (8.4% of
isolates), (p-value <0.001). Antibiotic-resistant isolates displayed resistance to common antimicrobial drugs used for
UTIs treatment in South Kivu province, namely: ciprofloxacin, ampicillin and third generation cephalosporins.
ESBL-phenotype was present in 92.9% of antibiotic-resistant isolates. Only amikacin, nitrofurantoin and imipenem
displayed satisfactory activity against antibiotic resistant isolates.
Conclusions: This study confirms the presence of antibiotic-resistant uropathogens (mainly ESBL-producers isolates)
at the Bukavu General Hospital. This study should serve as a wake-up call and help to raise awareness about the
threat to public health of antibiotic resistance in this DRC province.
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Urinary tract infections (UTIs) refer to any type of urothe-
lial inflammatory response resulting from the invasion of
the urinary tract by microbial pathogens [1,2]. They are
considered to be the most common bacterial infections
worldwide, whether in the community or hospital setting* Correspondence: leonid.irenge@uclouvain.be
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unless otherwise stated.[3-5]. While UTIs are well documented worldwide [6-20],
there are currently no reports on UTIs prevalence in
DRC, the second largest Africa country. The country has
been plagued by a protracted civilian war which has
claimed an estimated five million lives [21], with nearly
60% of all deaths caused by infectious diseases [22-24].
Accordingly, the aim of this study was to monitor the
rate of resistant urinary pathogens isolated from patients
with UTIs (both from community and hospital settings)
attending Bukavu Provincial Hospital (South Kivu, DRC)
from September 2012 to August 2013, as well as toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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used antimicrobial agents in the province.
Materials and methods
Study population and bacterial isolates
This cross-sectional study was conducted in both outpa-
tients and inpatients suspected of UTI at the Bukavu
Provincial Hospital. This hospital is one of the main
healthcare facilities of Bukavu, a city of more than 500
000 inhabitants. The hospital also serves as the health
reference center for the province of South-Kivu. It has
385 beds with 6400 admissions and 4900 outpatients per
year.
Urinary samples were collected in sterile universal
containers from patients presenting with UTI symptoms
(dysuria, pelvic pain, with or without fever) from September
2012 to August 2013. Exclusion factors were structural
or functional abnormalities of the genitourinary tract.
Catheterized patients were also excluded. Samples were
cultured within 30 minutes of collection. Samples dis-
playing pyuria (white blood cell count greater than 5 per
high-power field upon light microscopic examination)
and/or bacteriuria 105 CFU per mL were further processed
for culture and subsequent antimicrobial susceptibility test-
ing. Each specimen was cultured using a 10 μL calibrated
loop to inoculate cysteine lactose electrolytes deficient
(CLED) agar and incubated at 37°C for 16–24 hours and
the number of colonies was counted. A growth of >105
colony forming units/mL of one type of organism was
considered as significant bacteriuria. Identification was
performed using standard biochemical tests [25].
Ethical approval for the study was granted by the
Institutional Review Board (IRB) of the Université
Catholique de Bukavu, DRC. The study complied with the
World Health Organization and international guidelines
on antibiotic surveillance for which no recommendation
for an informed consent has been issued. In order to en-
sure confidentiality, samples were analyzed anonymously.
Antimicrobial susceptibility testing
The isolates were tested by the disk diffusion method on
Muller Hinton agar II and the results were interpreted
according to the guidelines European Committee on
Antimicrobial Susceptibility Testing (EUCAST, 2013) [26].
Antibiotic disks were purchased from Bio-Rad (Nazareth
Eke, Belgium). The following antibiotics were tested:
amikacin, ampicillin, amoxicillin, amoxicillin-clavulanic
acid, ceftriaxone, ceftazidime, imipenem, trimethoprim-
sulfamethoxazole, amikacin, ciprofloxacin, nitrofurantoin.
Isolates showing resistance to at least one cephalosporin
were tested for ESBL production by the double-disk syn-
ergy test on Mueller-Hinton agar (Biorad, Nazareth Eke;
Belgium) using ceftazidime and ceftriaxone placed at a dis-
tance of 20 mm apart from a disk containing amoxicillinplus clavulanic acid. A clear-cut enhancement of the in-
hibition in front of either ceftazidime and ceftriaxone
disks towards the clavulanic acid-containing disk (also
called “champagne-cork” or “keyhole”) was interpreted as
positive for ESBL production [27]. E-test strips (BioMérieux,
Marcy l’Etoile, France) were used for confirmation of ESBL
production. Minimum inhibitory concentrations (MIC) of
cefotaxime and ceftazidime with and without clavulanic
acid were determined, after 16–18 hours incubation on
Mueller Hinton plates inoculated with suspension of iso-
lates at a fixed density (0.5 to 0.6 McFarland standard).
The test was performed and interpreted according to the
manufacturer’s instructions. Escherichia coli ATCC 35218
and Klebsiella pneumoniae ATCC 700603 strains were used
as ESBL negative and positive controls respectively. Twenty
ampicillin and/or third-generation cephalosporins-resistant
isolates (n = 20) were tested for the presence of the beta-
lactamase AmpC phenotype, using cefoxitin-cloxacillin disk
diffusion test as described by Tan et al. [28]. Multi-drug
resistance was defined as non-susceptibility to at least one
agent in three or more antimicrobial categories [29]. All
multi-drug resistant isolates were cryopreserved at −80°C
for further studies.
Statistical analysis
Statistical analyses were performed using the SPSS statis-
tical package release 12.0 for Windows (SPSS, Inc., Chicago,
IL). Differences in group proportions and categorical
variables were assessed using the chi-square test. A
p-value <0.05 was considered as statistically significant.
Findings
Clean-catch midstream urine specimens (n = 2724) were
processed during the 12-month study period (from
September 1st 2012 until August 31st 2013) among which
1130 (41.2%), and 1594 (58.5%) were sampled from outpa-
tients and inpatients, respectively. Of these 2724 samples,
643 (23.6%) yielded significant growth of a single organ-
ism. Among positive samples (n = 643), 35.0%, and 65.0%
were isolated from outpatients and inpatients respectively.
The mean age of the study population was 27.2 years, with
a range of 0–75 years. Children between 0 and 17 years
represented 20.6% of all patients. The female to male ratio
was 1.73.
Escherichia coli was the most frequent uropathogen
isolated (376 out of 643; 58.5%) at the Bukavu General
Hospital both in outpatients and in inpatients. Klebsiella
spp. and Enterobacter spp. represented 21.9% and 16.2%
of uropathogens. Rare uropathogens included Citrobacter
spp., Proteus spp., and Acinetobacter spp. A summary of
antimicrobial susceptibility patterns of the most frequent
uropathogens is presented in Table 1.
16.3% isolates (n = 643) displayed a MDR phenotype.
Multidrug resistance rate was higher in inpatients isolates
Table 1 Antibiotic-resistance global rate (%) of UTI isolates (n = 643) collected at the Bukavu Hospital, South Kivu, DRC
Antimicrobial drug Escherichia coli Klebsiella spp. Enterobacter spp. Citrobacter spp. Proteus spp. Acinetobacter spp.
(n = 376) (n = 146) (n = 104) (n = 18)* (n = 2)* (n = 2)*
Amikacin 9.3 2.7 2.9 5.6 100 0
Amoxycillin 16.0 13.7 17.3 16.7 100 100
Ampicillin 16.0 13.7 17.3 16.7 100 100
Amoxicillin/clavulanic acid 16.0 13.7 15.4 11.7 100 0
Ceftazidime 16.0 13.7 17.3 16.7 100 100
Ceftriaxone 15.7 13.7 17.3 16.7 100 100
Cefuroxine 15.7 13.7 17.3 16.7 100 100
Ciprofloxacine 15.4 11.7 14.4 16.7 100 100
Imipenem 0 0 1 0 0 0
Nitrofurantoin 3.5 2.1 4.8 0 0 0
Sulfamethoxazole/Trimethoprim 15.4 13.7 17.3 16.7 100 100
*Caution regarding antibiotic-resistance rates, given the low number of isolates assayed.
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Among these MDR isolates, 92.4% displayed an ESBL
phenotype. Nitrofurantoin susceptibility for E. coli, En-
terobacter spp. and Klebsiella spp. was 69.6%, 78.9%,
and 83.3%, respectively. Uropathogens susceptibility
rates to amikacin were 42.1%, 69.6% and 77.8% for E.
coli, Enterobacter spp. and Klebsiella spp., respectively.
Regarding imipenem, all isolates but one, were susceptible
in vitro. This single imipenem non-susceptible isolate was
identified as an Enterobacter spp. Preliminary molecular
data obtained on 25 isolates showed that the CTX-M
group 1 gene was the most common in ESBL-producing
isolates assayed. Regarding beta-lactamases AmpC, no
isolate out of the 20 isolates assayed displayed this
phenotype.
Discussion
The steady increase of bacteria resistance to antibiotics
is a cause of global concern. Infections caused by resist-
ant microorganisms often fail to respond to the standard
treatment, resulting in prolonged illness and greater risk
of death [30]. Available studies from several Sub-Saharian
countries in Africa have highlighted unexpected high
levels of resistance of uropathogens to common antibi-
otics [9-12,14,16,17,31]. Unfortunately, there are no data
on rates of antibiotic resistance of uropathogens in DRC.
In that respect, recent data on Salmonella isolates from
blood cultures in DRC have shown high levels of antibiotic
resistance [32-34].
Accordingly, the goal of this work was to provide a
benchmark for the prevalence and patterns of antibiotic
resistance of bacterial pathogens involved in UTIs at the
Bukavu General Hospital. This study confirmed that
E. coli was the most common bacterial uropathogen
isolated from both in inpatients and outpatients at theBukavu Hospital. Besides E.coli, other bacterial species
such as Klebsiella spp. and Enterobacter spp. were also
frequently encountered. Noteworthy, we were not able
to isolate any Group B Streptococcus (GBS), though GBS
have been reported as causative agents of UTIs [35].
This possible bias might be linked to the sole use of CLED
medium for uropathogens isolation. It has indeed been
previously reported that the identification of Streptococcus
agalactiae on CLED agar could be challenging [36].
Limitations also include the possibility of selection bias
due to the fact that Bukavu Hospital mostly deals with
patients who had been treated with antibiotics prior to
their visit. Finally, our study may have underestimated
the prevalence of UTIs by using our current threshold of
105 CFU/mL of urine sample as a pre-requisite for urine
culture. Several studies have shown indeed that using
lower CFU threshold values improve the identification
of UTIs [37,38].
Our study found that the overall prevalence of antibac-
terial drug resistance was lower than recently reported in
neighboring countries [12,20]. A recent study in neighbor-
ing Rwanda reported resistance rates of 59.2%, 32.1% and
41.3% for amoxicillin/clavulanic acid, ceftriaxone and
ciprofloxacillin, respectively [20].
Regarding the pattern of resistance in the 105 drug-
resistant isolates, there was a striking low susceptibility to
ampicillin, amoxicillin, amoxicillin/clavulanic, cefuroxime,
ceftazidime, ceftriaxone, ciprofloxacin and sulfamethoxa-
zole/trimethoprim (see Table 2). Conversely, susceptibility
rates for rare pathogens as reported in this study (Citro-
bacter spp., Proteus spp.and Acinetobacter spp.) should
be interpreted with caution, as they were based on a re-
stricted number of isolates, and could therefore result in
observational bias with overestimation of effect size.
Interestingly, this study showed that ESBL-production
Table 2 Antibiotic resistance rates among MDR uropathogen isolates (n = 105) at the Bukavu General Hospital
Antimicrobial agent E. coli Enterobacter spp. Klebsiella spp. Citrobacter spp.* Proteus spp* Acinetobacter spp*
(n = 57) (n = 23) (n = 18) (n = 3) (n = 2) (n = 2)
ESBL-producing (%) phenotype 98.2 100.0 100.0 100.0 100.0 0
Amikacin (%) 57.9 30.4 22.2 33.3 100.0 0
Amoxycillin (%) 100.0 100.0 100.0 100.0 100.0 100.0
Ampicillin (%) 100.0 100.0 100.0 100.0 100.0 100.0
Amoxicillin/clavulanic acid (%) 84.2 87.0 100.0 66.7 100.0 0
Ceftazidime (%) 100.0 100.0 100.0 100.0 100.0 100.0
Ceftriaxone (%) 98.2 100.0 100.0 100.0 100.0 100.0
Cefuroxine (%) 98.2 100.0 100.0 100.0 100.0 100.0
Ciprofloxacine (%) 96.5 82.6 83.3 100.0 100.0 100.0
Imipenem (%) 0 4.3 0 0 0 0
Nitrofurantoin (%) 21.1 30.4 16.7 0 0 0
Sulfamethoxazole/trimethopim (%) 96.5 100.0 100.0 100.0 100.0 100.0
*Caution regarding antibiotic-resistance rates, given the low number of isolates assayed.
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and inpatients at the Bukavu hospital. Global susceptibility
rate of uropathogens to nitrofurantoin was 78.6%. The
susceptibility of antibiotic-resistant isolates to amikacin,
nitrofurantoin and to imipenem was high, which is a sig-
nificant observation in terms of management of UTIs. To
the best of our knowledge, this is the first study in DRC
(South-Kivu Province) on the rate of resistant and/or
ESBL-producing uropathogens.
Carbapenems have been recently introduced in the
province for treatment of ESBL-producing Enterobacteria,
and this study demonstrated very high susceptibility
among uropathogens. Based on our findings, we advo-
cate prescription of nitrofurantoin as the first-line anti-
biotics for UTIs treatment in South Kivu. Despite high
susceptibility to imipenem, it is critical to warn physi-
cians about the danger of prescribing this compound
as first-line antibiotic for UTIs treatment, because this
habit will likely enhance the emergence of imipenem-
resistant bacteria. Likewise, several other antibiotics previ-
ously reported as active against uropathogens in other
studies [7,39-41] but not currently prescribed in South
Kivu should be tested against MDR-resistant uropathogens.
These include drugs such as Fosfomycin [42], Piperacillin/
Tazobactam [39], Fosmomycin/tromethamol [40], cefe-
pime, tigecycline, temocillin [7,41] and other carbape-
mens [19]. But most importantly, it will be important
to put emphasis on public and professional education
towards a rational use of antibiotics, i.e. antibiotherapy
based on susceptibility patterns of pathogens, promo-
tion and evaluation of medical and veterinary practice
guidelines. Curbing the spread of antibiotic resistant
pathogens in the province and in the country will also
entail to deal with other critical issues which should beinvestigated. These include controlling the influx of
counterfeit drugs, and dealing with issues related to af-
fordability of healthcare in the province.
Conclusions
High rates of ESBL-producing Gram-negative bacteria were
found among inpatients and outpatients at the Bukavu
Hospital in DR Congo. Most of these ESBL-producing iso-
lates were also multidrug resistant, except for amikacin,
nitrofurantoin and imipenem for which susceptibility was
high.
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